SUSMED,Inc. Financial Summary for the First Quarter of the Fiscal Year Ending June 2027 (Japanese GAAP) (Non-consolidated)

Overview of Results

Segment revenue from the DTx business and the DTx platform business totaled 227.917 million yen for the first quarter cumulative period (including 26,963 thousand yen from the DTx platform business and 200,954 thousand yen from the DTx product business). On a company-wide basis, operating loss was 61,914 thousand yen, ordinary loss was 61,047 thousand yen, and quarterly net loss was 203,339 thousand yen, with an impairment loss of 141,341 thousand yen recorded as an extraordinary loss. Milestone revenue of 200 million yen was received in connection with the termination of the sales collaboration for an insomnia app that had been covered by insurance. The company intends to continue prioritizing research and development progress while aiming to maximize long-term profitability.

Outlook and Capital/Financial Trends

The full-year earnings forecast remains unchanged from the previously announced guidance, with revenue expected to increase 68.7% year-over-year. However, an operating loss is still forecast, and the recording of extraordinary losses including impairment could affect the financial position. Assets stood at 4,021,750 thousand yen in current assets, 166,990 thousand yen in non-current assets, and 3,886,815 thousand yen in net assets. The number of stock acquisition rights has increased, which may affect shareholder composition.